Sangamo Therapeutics, Inc.
SGMO
$0.6532
$0.083114.58%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.55M | 49.41M | 356.00K | 481.00K | 2.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.55M | 49.41M | 356.00K | 481.00K | 2.04M |
| Cost of Revenue | 23.68M | 27.73M | 24.82M | 35.29M | 50.91M |
| Gross Profit | -16.12M | 21.68M | -24.47M | -34.81M | -48.86M |
| SG&A Expenses | 9.77M | 8.65M | 14.75M | 11.47M | 13.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.44M | 36.38M | 39.57M | 46.76M | 64.11M |
| Operating Income | -25.89M | 13.03M | -39.21M | -46.28M | -62.06M |
| Income Before Tax | -23.82M | 10.76M | -36.05M | -48.99M | -60.57M |
| Income Tax Expenses | -427.00K | 88.00K | 74.00K | 98.00K | -272.00K |
| Earnings from Continuing Operations | -23.40M | 10.67M | -36.13M | -49.09M | -60.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.40M | 10.67M | -36.13M | -49.09M | -60.30M |
| EBIT | -25.89M | 13.03M | -39.21M | -46.28M | -62.06M |
| EBITDA | -24.65M | 14.25M | -37.97M | -44.87M | -60.24M |
| EPS Basic | -0.11 | 0.05 | -0.17 | -0.27 | -0.34 |
| Normalized Basic EPS | -0.07 | 0.04 | -0.12 | -0.15 | -0.21 |
| EPS Diluted | -0.12 | 0.04 | -0.17 | -0.27 | -0.34 |
| Normalized Diluted EPS | -0.07 | 0.04 | -0.12 | -0.15 | -0.21 |
| Average Basic Shares Outstanding | 210.19M | 208.35M | 203.95M | 180.34M | 177.62M |
| Average Diluted Shares Outstanding | 210.19M | 214.33M | 203.95M | 180.34M | 177.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
